A detailed history of Two Sigma Investments, LP transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Two Sigma Investments, LP holds 126,183 shares of WVE stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126,183
Previous 124,679 1.21%
Holding current value
$1.7 Million
Previous $622,000 66.24%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.12 - $9.01 $7,700 - $13,551
1,504 Added 1.21%
126,183 $1.03 Million
Q2 2024

Aug 14, 2024

SELL
$4.38 - $6.48 $1.28 Million - $1.89 Million
-292,046 Reduced 70.08%
124,679 $622,000
Q1 2024

May 15, 2024

BUY
$3.54 - $6.84 $1.38 Million - $2.67 Million
390,182 Added 1470.0%
416,725 $2.57 Million
Q4 2023

Feb 14, 2024

BUY
$4.16 - $6.87 $110,418 - $182,350
26,543 New
26,543 $134,000
Q4 2022

Feb 14, 2023

BUY
$3.18 - $7.0 $334,729 - $736,827
105,261 Added 165.33%
168,927 $1.18 Million
Q3 2022

Nov 14, 2022

BUY
$2.37 - $4.28 $150,888 - $272,490
63,666 New
63,666 $230,000
Q1 2022

May 16, 2022

SELL
$2.0 - $3.28 $75,796 - $124,305
-37,898 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$3.14 - $5.15 $118,999 - $195,174
37,898 New
37,898 $119,000
Q3 2021

Nov 15, 2021

SELL
$4.89 - $7.12 $256,724 - $373,800
-52,500 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$5.65 - $7.47 $202,835 - $268,173
35,900 Added 216.27%
52,500 $350,000
Q1 2021

May 17, 2021

BUY
$5.61 - $12.01 $19,635 - $42,035
3,500 Added 26.72%
16,600 $93,000
Q4 2020

Feb 16, 2021

BUY
$6.99 - $9.26 $91,569 - $121,306
13,100 New
13,100 $103,000
Q1 2018

May 15, 2018

SELL
$32.45 - $54.7 $765,852 - $1.29 Million
-23,601 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$21.8 - $39.35 $514,501 - $928,699
23,601
23,601 $828,000

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.17B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.